Glaukos Corporation has recently been upgraded to a "Buy" rating by UBS due to their innovative approach to ophthalmic treatments.

The company specializes in developing drop-free therapies for glaucoma, corneal diseases, and retinal disorders. Their product offerings include microinvasive glaucoma surgery solutions that use microscopic devices to lower intraocular pressure by restoring natural fluid outflow. They are also developing pharmaceutical products that utilize intracameral drug delivery technology for sustained release of glaucoma medications within the eye.

In addition, Glaukos markets transdermal drugs for ocular conditions such as dry eye and presbyopia, as well as bio-erodible, sustained-release implants to improve vision.